Floatz logo

Setmelanotide

Bardet-Biedl Syndrome

Tom Hühneprotein_peptidePhase 4 / ApprovedActive
A
81/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
71/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Bardet-Biedl Syndrome cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Setmelanotide is also rated in:

Alstrom syndromeActive
BBB
Indicative · Phase 4
75 / 100
View asset →
inherited obesityActive
BBB
Indicative · Phase 3
73 / 100
View asset →
obesity due to pro-opiomelanocortin deficiencyActive
BB
Indicative · Phase 3
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →